Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$712.20
+1.2%
$611.18
$510.05
$716.62
$43.59B0.41379,007 shs353,562 shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$81.48
+0.3%
$78.31
$64.00
$83.00
$47.84B1.073.80 million shs2.74 million shs
Icon Plc stock logo
ICLR
Icon
$177.94
+1.7%
$162.45
$125.10
$328.04
$14.37B1.2930,373 shs552,310 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%+7.91%+5.70%+21.83%+37.67%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.00%-0.34%+2.75%+4.42%+16.46%
Icon Plc stock logo
ICLR
Icon
0.00%+1.20%+6.91%+38.04%-44.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
3.5993 of 5 stars
2.52.00.00.02.71.74.4
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
4.3266 of 5 stars
2.33.00.04.03.02.52.5
Icon Plc stock logo
ICLR
Icon
4.0685 of 5 stars
3.45.00.00.01.73.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.09
Buy$766.507.62% Upside
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
2.65
Moderate Buy$85.905.43% Upside
Icon Plc stock logo
ICLR
Icon
2.75
Moderate Buy$218.3822.73% Upside

Current Analyst Ratings Breakdown

Latest ARGX, EW, and ICLR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
argenex SE stock logo
ARGX
argenex
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$818.00
8/26/2025
argenex SE stock logo
ARGX
argenex
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$750.00 ➝ $820.00
8/25/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$800.00
8/25/2025
argenex SE stock logo
ARGX
argenex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$850.00
8/21/2025
Icon Plc stock logo
ICLR
Icon
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$225.00 ➝ $200.00
8/7/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$84.00 ➝ $88.00
8/4/2025
argenex SE stock logo
ARGX
argenex
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $830.00
8/1/2025
argenex SE stock logo
ARGX
argenex
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$700.00 ➝ $766.00
8/1/2025
argenex SE stock logo
ARGX
argenex
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,060.00 ➝ $1,070.00
8/1/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$720.00 ➝ $774.00
7/31/2025
argenex SE stock logo
ARGX
argenex
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$741.00 ➝ $756.00
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$2.25B19.35$2.97 per share239.76$90.49 per share7.87
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$5.44B8.79$2.74 per share29.79$17.06 per share4.78
Icon Plc stock logo
ICLR
Icon
$8.09B1.78$20.04 per share8.88$117.92 per share1.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$19.5036.5265.640.8140.98%21.06%18.25%10/30/2025 (Estimated)
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$4.17B$6.9511.7229.633.9272.96%15.01%11.56%10/23/2025 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$9.7218.3111.642.639.82%10.95%6.23%10/22/2025 (Estimated)

Latest ARGX, EW, and ICLR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
argenex SE stock logo
ARGX
argenex
$2.84$3.74+$0.90$3.74$776.82 million$866.79 million
7/24/2025Q2 2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$0.62$0.67+$0.05$0.56$1.49 billion$1.53 billion
7/23/2025Q2 2025
Icon Plc stock logo
ICLR
Icon
$3.18$3.26+$0.08$2.30$1.98 billion$2.02 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.60
5.27
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.06
4.68
3.87
Icon Plc stock logo
ICLR
Icon
0.35
1.29
1.29

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
79.46%
Icon Plc stock logo
ICLR
Icon
95.61%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.34%
Icon Plc stock logo
ICLR
Icon
44.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.20 million59.71 millionOptionable
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
15,800587.10 million585.10 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable

Recent News About These Companies

The concept of health insurance and medical welfare. Circle wood and red heart with icon. Health insurance and access to health care.
3 Healthcare Pathbreakers With Long-Term Tailwinds (ICLR)
...
Icon (NASDAQ:ICLR) Given "Neutral" Rating at Citigroup
Assessing Icon: Insights From 8 Financial Analysts
Icon downgraded to Neutral from Buy at Citi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$712.20 +8.13 (+1.15%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$712.52 +0.31 (+0.04%)
As of 08/29/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$81.48 +0.25 (+0.30%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$81.24 -0.24 (-0.29%)
As of 08/29/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Icon stock logo

Icon NASDAQ:ICLR

$177.94 +2.89 (+1.65%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$177.94 +0.00 (+0.00%)
As of 08/29/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.